Ambu A/S
CSE:AMBU B
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
99.32
153.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ambu A/S
Ambu A/S
Cost of Revenue
Ambu A/S
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ambu A/S
CSE:AMBU B
|
Cost of Revenue
-kr2.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Cost of Revenue
-kr8.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
|
Demant A/S
CSE:DEMANT
|
Cost of Revenue
-kr5.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
V
|
ViroGates A/S
CSE:VIRO
|
Cost of Revenue
-kr1.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.
See Also
What is Ambu A/S's Cost of Revenue?
Cost of Revenue
-2.2B
DKK
Based on the financial report for Sep 30, 2024, Ambu A/S's Cost of Revenue amounts to -2.2B DKK.
What is Ambu A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-13%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Ambu A/S have been -13% over the past three years , -13% over the past five years .
You don't have any saved screeners yet
